Published in:
Open Access 01-12-2014 | Research article
RETRACTED ARTICLE: Anti-cancer effects of grailsine-al-glycoside isolated from Rhizoma Sparganii
Published in: BMC Complementary Medicine and Therapies | Issue 1/2014
Login to get accessAbstract
Background
An embryonic toxicity of Rhizoma
sparganii was observed in mice. This study was
aimed to evaluate the anticancer effects of
Grailsine-Al-glycoside, the bioactive component of Rhizoma sparganii, on estrogen
receptor-positive (ER+) and estrogen
receptor-negative (ER-) cancer cell
lines.
Methods
After A549, HeLa, HepG-2 and MCF-7 cells were treated with
Grailsine-Al-glycoside, cell proliferation was analyzed by MTT,
cell cycle and apoptosis by flow cytometry, and morphology with
an immunofluorescence microscope.
Results
Grailsine-Al-glycoside strongly suppressed cell proliferation
in a dose-dependent fashion in A549, MCF-7, HepG2, and HeLa
cells, though this growth inhibitory effect on HepG2 cells was
not as strong and long lasting. Compared to the control,
Grailsine-Al-glycoside caused a significant increase of
apoptosis in A549, MCF-7 and Hela cells. A549 and MCF-7 cells
were arrested at the G2/S phase whereas HepG2 cells were
arrested at the G1 phase by a high concentration of
Grailsine-Al-glycoside . Cell shapes were also changed by the
presence of Grailsine-Al-glycoside.
Conclusions
Grailsine-Al-glycoside from Rhizoma
sparganii inhibited the proliferation of
ER+ and some
ER- cancer cells.
Grailsine-Al-glycoside may be used as a chemotherapeutic agent
against ER+ and ERRα-expressing
ER- cancers.